Serious adverse events · people receiving palliative care irrespective of whether they had cancer with opioid‐induced bowel dysfunction
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse eventsg · people with cancer irrespective of whether receiving palliative care and with opioid‐induced bowel dysfunction
Low dose naldemedine showed no clear difference in serious adverse eventsg compared with higher doses (low certainty).
1 finding from 1 review
Intervention not reported
Adverse events ‐ myopathy · people with cardiovascular disease or at high risk of cardiovascular disease
It is very uncertain whether the intervention changes adverse events ‐ myopathy (very low certainty).
1 finding from 1 review
Adverse events grade 3 to 5 Range of · participants with recurrent (1‐course BCG failure) high‐risk non‐muscle invasive bladder cancer (49 men, 31 women)Country: Italy
It is very uncertain whether gemcitabine changes grade III–V adverse events compared with BCG (very low certainty).
1 finding from 1 review
Total serious adverse events · cardiovascular disease with high blood pressure
Lower blood pressure targets showed no clear difference in total serious adverse events compared with standard blood pressure targets (low certainty).
1 finding from 1 review
Adverse events: grade 1 to 2 · participants with recurrent (1‐course BCG failure) high‐risk non‐muscle invasive bladder cancer (49 men, 31 women)Country: Italy
It is very uncertain whether gemcitabine changes grade I or II adverse events compared with BCG (very low certainty).
1 finding from 1 review
Adverse events: atonic pupil · people with primary open‐angle glaucoma and no previous glaucoma surgery
Low‐ showed no clear difference in adverse events: atonic pupil compared with high‐energy diode trans‐scleral cyclophotocoagulation (low certainty).
1 finding from 1 review
Intervention not reported
Adverse events ‐ hepatopathy · people with cardiovascular disease or at high risk of cardiovascular disease
The intervention showed no clear difference in adverse events ‐ hepatopathy (low certainty).
1 finding from 1 review
Withdrawals due to adverse events · postmenopausal women with a higher risk for fracturesa
It is very uncertain whether intermittent/cyclic etidronate 400 mg/day changes withdrawals due to adverse events compared with placebo (very low certainty).
1 finding from 1 review
RR 1.09 [0.54, 2.18]
Studies not reported
Very low
Withdrawals due to adverse events · pPostmenopausal women at higher risk of fractures1
Risedronate 5 mg/day showed no clear difference in withdrawals due to adverse events compared with placebo (high certainty).
1 finding from 1 review
RR 0.98 [0.9, 1.07]
Studies not reported
High
Adverse eventsMeasurement unclear · overweight or obese adults
1 finding from 1 review
Patients with serious adverse events · Studies recruited adults and adolescents aged 12 and older with chronic asthma
SiT for maintenance/relief showed no clear difference in patients with serious adverse events compared with higher‐dose ICS/LABA + SABA (moderate certainty).
1 finding from 1 review
OR 0.92 [0.74, 1.13]
9130 participants
Moderate
Intervention not reported
Serious adverse events during treatment · participants with alcoholic hepatitis at high risk of mortality and morbidity
It is very uncertain whether the intervention changes serious adverse events during treatment (very low certainty).
1 finding from 1 review
Intervention not reported
Major adverse cardiovascular events (MACE) · people with cardiovascular disease or at high risk of cardiovascular disease
The intervention probably leads to lower major adverse cardiovascular events (MACE) (moderate certainty).
1 finding from 1 review
Adverse events (e.g. ulcers, tooth staining) · Children and adolescents below 18 years at study start (included studies: children from birth to 15 years), with mixed, permanent or…
1 finding from 1 review
Intervention not reported
Discontinuation of study drug due to adverse events · unvaccinated, non‐hospitalized people with mild symptomatic COVID‐19 (WHO scale 2 to 3) at high risk for progression to severe disease
The intervention probably leads to lower discontinuation of study drug due to adverse events (moderate certainty).
1 finding from 1 review
Intervention not reported
Adverse events not estimable · Patients with refractory/relapsed Hodgkin lymphoma
1 finding from 1 review
Intervention not reported
Participants with non‐serious adverse events: up to 3 months' · participants with alcoholic hepatitis at high risk of mortality and morbidity
It is very uncertain whether the intervention changes participants with non‐serious adverse events: up to 3 months' (very low certainty).
1 finding from 1 review
Serious adverse events (falls) Median · older people at risk of poor health outcomes
It is very uncertain whether comprehensive Geriatric Assessment changes serious adverse events (falls) Median compared with usual care (very low certainty).
1 finding from 1 review
Intervention not reported
Incidence of adverse events ‐ overall · children with HIV infection aged 12 years and under
The intervention showed no clear difference in incidence of adverse events ‐ overall (moderate certainty).
1 finding from 1 review